Literature DB >> 7313573

The bacteriology of acute otitis media in children with special reference to Streptococcus pneumoniae as studied by bacteriological and antigen detection methods.

J Luotonen, E Herva, P Karma, M Timonen, M Leinonen, P H Mäkelä.   

Abstract

The middle ear fluid (MEF) was studied during an acute attack of otitis media in 519 children, aged 3 months to 6 years. Streptococcus pneumoniae (Pn) was cultured from 39% of the cases; serotypes 19, 6, 3 and 23 were the most common. Haemophilus influenzae (Hi) was cultured in 12%; only 2/64 strains were of type b. Pn were found equally often in all age groups, but Hi were significantly less often isolated in children older than 3 years. The number of negative cultures increased with the age of the child. Pneumococcal capsular polysaccharide was detected with counterimmunoelectrophoresis and/or latex agglutination in 83% of the MEFs from which Pn were cultured, but also in about one third of the MEFs from which no bacteria could be grown. Altogether, with these methods combined Pn were implicated in nearly 60% of the cases of acute otitis media. Gram staining showed polymorphonuclear leucocytes in 85% of pneumococcal otitis cases that were verified by culture but also in 72% of the cases from which no bacteria could be cultured, supporting the contention that also these latter are usually caused by bacteria.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7313573     DOI: 10.3109/inf.1981.13.issue-3.04

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  22 in total

Review 1.  Acute otitis media.

Authors:  S Pirozzo; C Del Mar
Journal:  West J Med       Date:  2001-12

2.  Evaluation of the virulence of a Streptococcus pneumoniae neuraminidase-deficient mutant in nasopharyngeal colonization and development of otitis media in the chinchilla model.

Authors:  H H Tong; L E Blue; M A James; T F DeMaria
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children.

Authors:  Ravinder Kaur; Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2011-08       Impact factor: 2.129

4.  Early structural changes in the rat tympanic membrane during pneumococcal otitis media.

Authors:  K Magnuson; S Hellström
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

5.  Surface-exposed and antigenically conserved determinants of outer membrane proteins of Branhamella catarrhalis.

Authors:  T F Murphy; L C Bartos
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

6.  Microbiological perspectives of co-trimoxazole.

Authors:  A Bauernfeind; G Hörl; B Przyklenk
Journal:  Infection       Date:  1987       Impact factor: 3.553

7.  Penicillin treatment accelerates middle ear inflammation in experimental pneumococcal otitis media.

Authors:  M Kawana; C Kawana; G S Giebink
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

8.  Ability of pneumococcal serotypes and clones to cause acute otitis media: implications for the prevention of otitis media by conjugate vaccines.

Authors:  William P Hanage; Kari Auranen; Ritva Syrjänen; Elja Herva; P Helena Mäkelä; Terhi Kilpi; Brian G Spratt
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

10.  Comparison of PCR assay with bacterial culture for detecting Streptococcus pneumoniae in middle ear fluid of children with acute otitis media.

Authors:  A Virolainen; P Salo; J Jero; P Karma; J Eskola; M Leinonen
Journal:  J Clin Microbiol       Date:  1994-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.